Tim Hulsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2494655/publications.pdf

Version: 2024-02-01

623734 501196 2,365 34 14 28 citations h-index g-index papers 37 37 37 5846 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	BioVenn $\hat{a}\in$ " a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams. BMC Genomics, 2008, 9, 488.	2.8	1,371
2	From Big Data to Precision Medicine. Frontiers in Medicine, 2019, 6, 34.	2.6	273
3	Benchmarking ortholog identification methods using functional genomics data. Genome Biology, 2006, 7, R31.	9.6	139
4	Identification of novel functional TBP-binding sites and general factor repertoires. EMBO Journal, 2007, 26, 944-954.	7.8	97
5	Semantics in active surveillance for men with localized prostate cancer — results of a modified Delphi consensus procedure. Nature Reviews Urology, 2017, 14, 312-322.	3.8	65
6	Sharing Is Caringâ€"Data Sharing Initiatives in Healthcare. International Journal of Environmental Research and Public Health, 2020, 17, 3046.	2.6	65
7	Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. European Urology, 2019, 75, 523-531.	1.9	58
8	Heavier-than-air flying machines are impossible. FEBS Letters, 2004, 564, 269-273.	2.8	51
9	The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date. BJU International, 2018, 121, 737-744.	2.5	51
10	Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundationâ∈™s Global Action Plan Prostate Cancer Active Surveillance Initiative. European Urology Oncology, 2020, 3, 80-91.	5.4	24
11	Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. European Urology, 2019, 76, 693-702.	1.9	18
12	Evolution of Closely Linked Gene Pairs in Vertebrate Genomes. Molecular Biology and Evolution, 2008, 25, 1909-1921.	8.9	17
13	An overview of publicly available patient-centered prostate cancer datasets. Translational Andrology and Urology, 2019, 8, S64-S77.	1.4	15
14	Personalised biopsy schedules based on risk of Gleason upgrading for patients with lowâ€risk prostate cancer on active surveillance. BJU International, 2021, 127, 96-107.	2.5	15
15	BioVenn– an R and Python package for the comparison and visualization of biological lists using area-proportional Venn diagrams. Data Science, 2021, 4, 51-61.	0.9	14
16	PhyloPat: phylogenetic pattern analysis of eukaryotic genes. BMC Bioinformatics, 2006, 7, 398.	2.6	13
17	Testing statistical significance scores of sequence comparison methods with structure similarity. BMC Bioinformatics, 2006, 7, 444.	2.6	13
18	Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. European Urology Open Science, 2022, 35, 59-67.	0.4	13

#	Article	IF	CITATIONS
19	PhyloPat: an updated version of the phylogenetic pattern database contains gene neighborhood. Nucleic Acids Research, 2009, 37, D731-D737.	14.5	8
20	Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. European Urology Oncology, 2019, 2, 333-336.	5.4	8
21	958 Integrating large datasets for the Movember Global Action Plan on active surveillance for low risk prostate cancer. European Urology Supplements, 2016, 15, e958.	0.1	7
22	Challenges and solutions for big data in personalized healthcare. , 2021, , 69-94.		7
23	Identification of new biomarker candidates for glucocorticoid induced insulin resistance using literature mining. BioData Mining, 2013, 6, 2.	4.0	5
24	The ten commandments of translational research informatics. Data Science, 2019, 2, 341-352.	0.9	3
25	Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database. European Urology Open Science, 2021, 34, 47-54.	0.4	3
26	Data Science in Healthcare: COVID-19 and Beyond. International Journal of Environmental Research and Public Health, 2022, 19, 3499.	2.6	3
27	Developing a future-proof database for the European Randomized study of Screening for Prostate Cancer (ERSPC). European Urology Supplements, 2019, 18, e1766.	0.1	2
28	The ReIMAGINE Multimodal Warehouse: Using Artificial Intelligence for Accurate Risk Stratification of Prostate Cancer. Frontiers in Artificial Intelligence, 2021, 4, 769582.	3.4	2
29	Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database. Prostate, 2022, 82, 876-879.	2.3	2
30	Literature analysis of artificial intelligence in biomedicine. Pharmacogenomics Research and Personalized Medicine, 0, .	0.0	1
31	The Construction of Genome-Based Transcriptional Units. OMICS A Journal of Integrative Biology, 2009, 13, 105-114.	2.0	0
32	A first step towards a global nomogram to predict disease progression for men on active surveillance. Translational Andrology and Urology, 2021, 10, 1102-1109.	1.4	0
33	International AS Registry: The Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative. Current Clinical Urology, 2018, , 135-147.	0.0	0
34	MP70-02 AN OVERVIEW OF PUBLICLY AVAILABLE PATIENT-CENTERED PROSTATE CANCER DATASETS. Journal of Urology, 2018, 199, .	0.4	0